MSA Team Works Toward Publications

March 16, 2020

MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating the pharmacokinetics (nasal absorption), pharmacodynamics (efficacy), and safety in support of Bryn Pharma’s goal to bring a cost-effective intranasal delivery system for patients with anaphylaxis to market.

MSA authors include Principals Dr. Kenneth Dretchen Ph.D., Zack Mesa, and Michael Mesa, along with MSA associate Matt Robben Ph.D.

MSA News

MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application

FREDERICK, MD.  Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…

Read More

Mesa Science Associates Receives Grant to Begin Study of a Treatment for Marfan Syndrome

Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…

Read More

NIH SBIR Grant application 1/5/2022

Mesa Science Associates has applied for an NIH Small Business Innovative Research (SBIR) Grant from the National Institutes of Health…

Read More